

ORIGINAL

**TSCA NON-CONFIDENTIAL BUSINESS INFORMATION**

DOCUMENT DESCRIPTION	DOCUMENT CONTROL NUMBER	DATE RECEIVED
8EHQ-10-17913	88100000242	4/19/10

COMMENTS:

**DOES NOT CONTAIN CBI**

MR326274


 RECEIVED  
 OPPT CBIC

10 APR 19 AM 10:59

 DuPont Haskell Global Centers  
 for Health and Environmental Sciences  
 1090 Elkton Road, P.O. Box 50  
 Newark, DE 19714-0050

April 16, 2010

Via Federal Express

 Document Processing Center (Mail Code 7407M)  
 Room 6428  
 Attention: 8(e) Coordinator  
 Office of Pollution Prevention and Toxics  
 U.S. Environmental Protection Agency, ICC Building  
 1201 Constitution Ave., NW  
 Washington, DC 20004


Dear 8(e) Coordinator:

Urea, N'-(3,4-dichlorophenyl)-N,N-dimethyl- (CAS # 330-54-1) [80%]

This letter is to inform you of the results of an acute inhalation toxicity study in rats with a proprietary mixture containing the above referenced substances.

A 4-hour nose-only acute inhalation LC50 in rats was conducted according to OECD Guideline No. 403. Five rats/sex were exposed to an atmosphere of the test mixture that was pulverized and nebulized into the inhalation chamber. The atmosphere was measured gravimetrically by taking 4 samples of the inhalation chamber. Aerodynamic particle size distribution was determined on 2 samples using a seven stage cascade impactor. The Mass Median Aerodynamic Diameter was 7.05  $\mu\text{m}$ , with a Geometric Standard Deviation of 1.8.

No animals died during the study. No exposure-related clinical signs were reported. No gross macroscopic changes were noted. A slight decrease in body weight was observed within the first 7 days. The inhalation LC50 was determined to be > 10.75 mg/L (male and female rats combined).

This information is submitted in accordance with current guidance issued by EPA indicating EPA's interpretation of Section 8(e) of the Toxic Substances Control Act or, where it is not clear that reporting criteria have been met, it is submitted as a precautionary measure and because it is information in which EPA may have an interest.

Sincerely,

 A. Michael Kaplan, Ph.D.  
 Director - Regulatory Affairs

 AMK/MB: clp  
 (302) 366-5260


**CONTAINS NO CBI**

